A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Iberdomide (Primary)
- Indications Sarcoidosis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 07 Nov 2019 Planned End Date changed from 1 Jun 2017 to 30 Jun 2017.
- 07 Nov 2019 Planned primary completion date changed from 1 Jun 2017 to 30 Jun 2017.
- 31 Aug 2018 Biomarkers information updated